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SynthesisAbstract A series of novel ﬂuoroquinolone derivatives bearing N-thiomide linkage with 6-substi-
tuted-2-aminobenzothiazole substituents at the C-7 position were synthesized to obtain potent ana-
logs active against bacterial strains. Some compounds exhibited excellent antibacterial activity
against Staphylococcus auerus, Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa bacterial
strains. Among all the synthesized compounds 6-nitro substituted benzothiazole along with norﬂox-
acin (4b) and gatiﬂoxacin (4l) showed MIC 05 lg/ml when tested against S. auerus.Moreover, com-
pounds 4d, 4f and 4l showed superior MIC (15, 10, and 15 lg/ml respectively) against B. subtilis.
The results of the present study reveal that the compounds have signiﬁcant antibacterial potential
and are suitable candidates for further exploration.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Since the introduction of ﬂuoroquinolones in late 1970s, they
have generated great excitement, opportunities and applica-
tions in the antibacterial chemotherapeutic world, as these
agents potentially offer all the general attributes of ideal anti-
bacterial agents. Over the last 15 years, researchers have at-
tempted and proved these attributes as reality (Andriole,
1988; Sharma and Jain, 2008). Initially, great improvement
in potency, spectrum and in vivo efﬁciency was achieved as a
Novel ﬂuoroquinolone derivatives bearing N-thiomide linkage with 6-substituted-2-aminobenzothiazoles: S569result of intensive structural modiﬁcations. Further, the sys-
tematic and well deﬁned structure–activity relationships were
established which reveal the optimal groups for each position
in terms of size, shape and electronic properties. Once the mul-
titude of new quinolones reached advanced toxicology and
clinical trials, it was realized that quinolones like all other
agents, do show some undesirable side effects in human and
the laboratory testings. Their adverse reactions and
toxicological proﬁles have been reviewed extensively (Lv et al.,
2012). The major concern has been the growing incidences of
resistance especially to Staphylococci and Enterococci. Some
of the side effects of quinolone antibacterials are unacceptable,
for example, grepaﬂoxacin withdrawn from the market, due to
increased cases of heart problems in clinical ﬁndings. Similarly
trovaﬂoxacin was removed from the market due to liver toxicity
(Graul et al., 1999). The current phase of quinolone design is
aimed at reducing or eliminating these side effects and overcome
the emerging resistance through additional synthetic manipula-
tions while further enhancing or maintaining potency.
Synthesis and evaluation of over 10,000 quinolone deriva-
tives resulted in extensive knowledge of the structure–activity
relationship for many quinolone substituents. The most inten-
sive structural variation has been carried out on amines at the
7-position (Foroumadi et al., 2006; Foroumadi et al., 2005),
partially due to the ease of their aromatic substitution reac-
tions. Piperazine, aminopyrrolidine and their substituted deriv-
atives have been the most successfully employed side chains, as
evidenced by the compounds currently in the market (Sharma
et al., 2009; Sharma et al., 2010; Domagala et al., 1988; Chu
et al., 1985). Originally, the newer ﬂuoroquinolones arose with
the development of 7- piperazinyl quinolones, such as norﬂox-
acin 1, ciproﬂoxacin 2 and gatiﬂoxacin 3 (Fig. 1). The site near
the C-7 substituent is regarded as drug enzyme interaction do-
main (Foroumadi et al., 2005).
These facts motivated our concern to prepare C-7 substitu-
ents of quinolones. The piperazine moiety of ﬂuoroquinolones
possesses enough structural ﬂexibility to allow product optimi-
zation. Thus, we anticipated that safer and superior antibacte-
rial compounds can be developed by attaching an appropriate
moiety through N-atom of the substituents at C-7 position. In
this communication, we report the synthesis, characterization
and antibacterial activity of a number of N-substituent piper-
azinyl quinolones by introducing speciﬁc substituents in the
piperazine unit of 7-piperazinyl quinolones.N
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Figure 1 Some commercially available ﬂuoroquinolones.Keeping in view the diverse biological activity proﬁle of 2-
amino-6-substituted benzothiazoles such as cytotoxic, antibac-
terial, fungicidal, analgesic, antiinﬂammatory, antioxidant
activities and pharmacological interventions of quinolone
derivatives such as antibacterial, antimycobacterial, antimalar-
ial, antioxidant, analgesic and antiviral activities, (Chu et al.,
1985; Senthilkumar et al., 2009; Jayashree et al., 2009; El-Gaz-
zar et al., 2009; Dinakaran et al., 2008; Winter et al., 2008;
German et al., 2008; Jazayeri et al., 2009) clubbing of these
scaffolds was considered to be of signiﬁcant relevance. More-
over, due to our ongoing endeavors (Sharma et al., 2010,
2011; Kharb et al., 2011, 2011a, b) and research program on
the design and synthesis of novel antimicrobial agents, a num-
ber of potent ﬂuoroquinolone derivatives(Lv et al., 2012; Shar-
ma and Jain, 2008; Sharma et al., 2011) have been synthesized.
Recently, we have reported the synthesis of novel ﬂuoroquin-
olone derivatives annulated with benzothiazoles with promis-
ing antibacterial activity (Sharma et al., 2011a, 2015). It was
clearly indicated that clubbing of ﬂuoroquinolone with benzo-
thiazoles is worthwhile and the synthesized compounds were of
promising pharmacological signiﬁcance. Thus, the present
study was aimed to achieve better antimicrobial proﬁle at low-
er concentrations, by preparing N-substituted piperazinyl
quinolone derivatives carrying benzothiazolyl substituents.
2. Experimental
2.1. General
All the chemicals and solvents used in this study were of labo-
ratory grade and procured from E. Merck (Germany) and S.
D. Fine Chemicals (India). Melting points were determined
on a Labindia MR-VIS visual melting point apparatus and
are uncorrected. The thin layer chromatography (TLC) plates
(Silica Gel G) were used to conﬁrm the purity of commercial
reagents used, compounds synthesized and to monitor the
reactions as well. Absorbance values against wavelength were
taken on a Systronic double beam UV-166 spectrophotometer.
The IR spectra were obtained on a Perkin Elmer IR spectro-
photometer (KBr pellet). 1H NMR spectra were recorded
using Bruker 400 spectrometer and chemical shifts are ex-
pressed as d (ppm) using tetramethylsilane as an internal stan-
dard in DMSO-d6. Mass spectra of some selected compounds
were obtained using a micromass-Q-TOF-micro spectrometer.
2.2. Chemistry
2.2.1. General procedure for the synthesis of 2-amino-6-
substituted benzothiazole [26] (2a–2e)
The 2-amino-6-substituted benzothiazoles (2a–2e) were pre-
pared by mixing p-substituted aniline (0.05 mol) (1a–1e) and
potassium thiocyanate (0.2 mol) in 90 ml of 96% acetic acid.
To this was added drop wise, with stirring, a solution of bro-
mine (0.05 mol) in glacial acetic acid (37.5 ml) and temperature
was maintained below 35 C. After all the bromine solution
was added, the mixture was stirred for another 10 h at room
temperature and was ﬁltered, the residue so obtained was
washed with water. The combined ﬁltrate and washings were
neutralized with ammonium hydroxide solution. The precipi-
tate thus obtained was collected and dried. Further puriﬁca-
tion was carried out by crystallization from benzene.
S570 P.C. Sharma et al.Adopting the above procedure, ﬁve different 2-amino-6-substi-
tuted benzothiazoles (2a–2e) have been synthesized. The purity
of the benzothiazoles was checked by TLC.
2.2.2. General procedure for the synthesis of ﬂuoroquinolone
derivatives (4a–4n)
For the synthesis of target ﬂuoroquinolone derivatives, a
mixture of 2-amino-6-substituted benzothiazole (0.05 mmol)
(2a–2e), ﬂuoroquinolone (0.05 mmol) (3a–3c) and carbon
disulﬁde (0.05 mmol) in basic medium composed of sodium
bicarbonate (NaHCO3) (0.05 mmol) and N,N-dimethyl form-
amide (10 ml), was reﬂuxed for 10 h. After complete consump-
tion of ﬂuoroquinolone in the reaction (monitored by thin
layer chromatography), the reaction mixture was poured into
ice cold water and the precipitate was ﬁltered, washed withTable 1 Structural and physicochemical data of target compounds
S
N
NH
N
R
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S
Compound R1 R2 R3 R
4a –C2H5 –H –H –OC
4b –C2H5 –H –H –NO
4c –C2H5 –H –H –CH
4d –C2H5 –H –H –F
4e –C2H5 –H –H –Br
4f –H –H –OC
4g –H –H –NO
4h –H –H –CH
4i –H –H –F
4j –H –H –Br
4k –OCH3 –CH3 –OC
4l –OCH3 –CH3 –NO
4m –OCH3 –CH3 –CH
4n –OCH3 –CH3 –Fwater to yield the crude product. The precipitate was collected
and dried. Further puriﬁcation was carried out by crystalliza-
tion from N,N-dimethyl formamide (DMF). The purity of title
compounds was ascertained by thin layer chromatography.
Employing the captioned procedure, fourteen novel target
compounds (4a–4n) were synthesized. Structural and physico-
chemical data of synthesized compounds are presented in
Table 1.
2.2.2.1. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-methoxy-1,3-benzothiazol-
2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4a).M.p. 247–250 C (67% yield).
1H NMR (DMSO-d6): d/ppm = 1.38 (3H, J = 6.7, t, CH3
ethyl), 2.49 (2H, J = 6.7, q, CH2 ethyl), 3.02–3.76 (8H, m,
piperazine), 3.93 (3H, s, OCH3 benzothiazole), 6.76–7.93(4a–4n).
N
N
O
OH
O
F
R1
R2
mp (C) Formula Yield (%)
H3 247–250 C25H24FN5O4S2 67
2 278–281 C24H21FN6O5S2 60
3 254–257 C25H24FN5O3S2 58
245–248 C24H21F2N5O3S2 72
256–259 C24H21BrFN5O3S2 69
H3 326–329 C26H24FN5O4S2 66
2 332–335 C25H21FN6O5S2 64
3 319–322 C26H24FN5O3S2 59
329–331 C25H21F2N5O3S2 64
327–330 C25H21BrFN5O3S2 63
H3 229–232 C28H28FN5O5S2 68
2 199–202 C27H25FN6O6S2 63
3 197–200 C28H28FN5O4S2 63
211–214 C27H25F2N5O4S2 64
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benzothiazole)}, 8.90 (1H, s, H2-quinolone), 9.36 (1H, s, NH),
15.14 (1H, s, COOH); IR (KBr): cm1 = 1585 (C = C), 1705
(C = O), 1211 (C–O), 1157 (C–N), 3186–2854 (C–H), 3302
(COOH); MS: m/z= 541.6 (M+).
2.2.2.2. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-nitro-1,3-benzothiazol-2-
yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4b).M.p. 278–281 C (60% yield).
1H NMR (DMSO-d6): d/ppm = 1.39 (3H, J = 7.2, t, CH3
ethyl), 2.19 (2H, J = 7.2, q, CH2 ethyl), 3.29–3.64 (8H, m,
piperazine), 7.18–8.15 {5H, m, Aromatic proton (H5, H8-quin-
olone and H4’, H5’, H7’-benzothiazole)}, 8.63 (1H, s, H2-quin-
olone), 9.35 (1H, s, NH), 15.24 (1H, s, COOH); IR (KBr): cm
1 = 1586 (C = C), 1718 (C = O), 1258 (C–O), 1052 (C–N),
2932 (C–H), 3415 (COOH); MS: m/z= 556.6 (M+).
2.2.2.3. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-methyl-1,3-benzothiazol-2-
yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4c).M.p. 254–257 C (58% yield).
1H NMR (DMSO-d6): d/ppm = 1.41 (3H, J = 6.6, t, CH3
ethyl), 2.29–2.49 (2H, J = 6.6, q, CH2 ethyl), 3.07–3.59 (8H,
m, piperazine), 2.89 (3H, s, CH3 benzothiazole), 6.98–7.93
{5H, m, Aromatic proton (H5, H8-quinolone and H4’, H5’,
H7’-benzothiazole)}, 8.10 (1H, s, H2 quinolone), 8.90 (1H, s,
NH), 15.19 (1H, s, COOH); IR (KBr): cm1 = 1583
(C = C), 1717 (C = O), 1262 (C-O), 1098 (C-N), 2922
(C-H), 3415 (COOH).
2.2.2.4. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-benzothiazol-2-
yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4d).M.p. 245–248 C (72% yield).
1H NMR (DMSO-d6): d/ppm = 1.37 (3H, J = 6.8, t, CH3
ethyl), 1.89 (2H, J = 6.8, q, CH2 ethyl), 3.31–4.28 (8H, m,
piperazine), 6.97–8.10 {5H, m, Aromatic proton (H5, H8-quin-
olone and H4’, H5’, H7’-benzothiazole)}, 8.89 (1H, s, H2-quin-
olone), 9.35 (1H, s, NH), 15.02 (1H, s, COOH); IR (KBr): cm
1 = 1586 (C = C), 1715 (C = O), 1255 (C–O), 1062 (C–N),
2933 (C–H), 3423 (COOH).
2.2.2.5. 7-(4-(N-(6-bromo-1,3-benzothiazol-2-yl)amino-1-thio-
methyl)piperazin-1-yl)-1-ethyl-6-ﬂuoro-1,4-dihydro-4-oxo-quin-
oline-3-carboxylic acid (4e). M.p. 256–259 C (69% yield). 1H
NMR (DMSO-d6): d/ppm = 1.38 (3H, J = 6.2, t, CH3 ethyl),
1.89 (2H, J = 6.2, q, CH2 ethyl), 2.95–3.93 (8H, m, pipera-
zine), 7.17–8.10 {5H, m, Aromatic proton (H5, H8-quinolone
and H4’, H5’, H7’-benzothiazole)}, 8.92 (1H, s, H2-quinolone),
9.56 (1H, s, NH), 15.26 (1H, s, COOH); IR (KBr): cm
1 = 1585 (C = C), 1715 (C = O), 1227 (C–O), 1050 (C–N),
2932 (C–H), 3409 (COOH).
2.2.2.6. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-methoxy-1,3-ben-
zothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-
dro-4-oxo-quinoline-3-carboxylic acid (4f). M.p. 326–329 C
(66% yield). 1H NMR (DMSO-d6): d/ppm = 1.32 (4H, d,
CH2-CH2- Cyclopropyl), 3.25 (1H, m, CH Cyclopropyl),
3.30–3.61 (8H, m, piperazine), 3.84 (3H, s, OCH3 benzothia-
zole), 7.43–8.11 {5H, m, Aromatic proton (H5, H8-quinolone
and H4’, H5’, H7’-benzothiazole)}, 8.60 (1H, s, H2-quinolone),
9.64 (1H, s, NH), 15.19 (1H, s, COOH); IR (KBr): cm
1 = 1581 (C = C), 1718 (C = O), 1257 (C-O), 1173 (C-N),
2924–2839 (C-H), 3294 (COOH).2.2.2.7. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-nitro-1,3-ben-
zothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-
dro-4-oxo-quinoline-3-carboxylic acid (4g). M.p. 332–335 C
(64% yield). 1H NMR (DMSO-d6): d/ppm = 1.34 (4H, d,
CH2-CH2- Cyclopropyl), 2.90 (1H, m, CH Cyclopropyl),
3.25–3.63 (8H, m, piperazine), 7.40–8.12 {5H, m, Aromatic
proton (H5, H8-quinolone and H4’, H5’, H7’-benzothiazole)},
8.23 (1H, s, H2-quinolone), 9.09 (1H, s, NH), 14.87 (1H, s,
COOH); IR (KBr): cm1 = 1584 (C = C), 1715 (C = O),
1258 (C–O), 1062 (C-N), 2936 (C-H), 3448 (COOH); MS: m/
z= 568.6 (M+).
2.2.2.8. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-methyl-1,3-ben-
zothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-
dro-4-oxo-quinoline-3-carboxylic acid (4h). M.p. 319–322 C
(59% yield). 1H NMR (DMSO-d6): d/ppm = 1.18 (4H, d,
CH2–CH2–Cyclopropyl), 2.87 (1H, m, CH Cyclopropyl),
3.33–3.80 (8H, m, piperazine), 2.49 (3H, s, CH3 benzothia-
zole), 7.38–8.21 {5H, m, Aromatic proton (H5, H8-quinolone
and H4’, H5’, H7’-benzothiazole)}, 8.65 (1H, s, H2-quinolone),
9.34 (1H, s, NH), 15.12 (1H, s, COOH); IR (KBr): cm
1 = 1584 (C = C), 1718 (C = O), 1265 (C–O), 1203 (C–N),
3094–2839 (C–H), 3294 (COOH).
2.2.2.9. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-ben-
zothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-
dro-4-oxo-quinoline-3-carboxylic acid (4i). M.p. 329–331 C
(64% yield). 1H NMR (DMSO-d6): d/ppm = 1.17 (4H, d,
CH2–CH2–Cyclopropyl), 3.12 (1H, m, CH Cyclopropyl),
3.20–3.95 (8H, m, piperazine), 7.00–8.11 {5H, m, Aromatic
proton (H5, H8-quinolone and H4’, H5’, H7’-benzothiazole)},
8.64 (1H, s, H2-quinolone), 9.29 (1H, s, NH), 15.09 (1H, s,
COOH); IR (KBr): cm1 = 1583 (C = C), 1717 (C = O),
1260 (C–O), 1057 (C–N), 2909 (C–H), 3416 (COOH).
2.2.2.10. 7-(4-(N-(6-bromo-1,3-benzothiazol-2-yl)amino-1-
thio-methyl)piperazin-1-yl)-1-cyclopropyl-6-ﬂuoro-1,4-dihydro-
4-oxo-quinoline-3-carboxylic acid (4j). M.p. 327–330 C (63%
yield). 1H NMR (DMSO-d6): d/ppm = 1.16 (4H, d, CH2–
CH2–Cyclopropyl), 3.02 (1H, m, CH Cyclopropyl), 3.28–3.80
(8H, m, piperazine), 7.19–8.11 {5H, m, Aromatic proton (H5,
H8-quinolone and H4’, H5’, H7’-benzothiazole)}, 8.60 (1H, s,
H2-quinolone), 9.64 (1H, s, NH), 15.22 (1H, s, COOH); IR
(KBr): cm1 = 1585 (C = C), 1717 (C = O), 1260 (C–O),
1061 (C–N), 2917 (C–H), 3448 (COOH); MS: m/z= 602.5
(M+).
2.2.2.11. 1-Cyclopropyl-6-ﬂuoro-8-methoxy-7-(4-(N-(6-meth-
oxy-1,3-benzothiazol-2-yl)amino-1-thio-methyl)-3-methylpi-
perazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
(4k). M.p. 229–232 C (68% yield). 1H NMR (DMSO-d6):
d/ppm = 1.27 (4H, d, CH2–CH2–Cyclopropyl), 2.82 (1H, m,
CH Cyclopropyl), 3.26–3.66 (7H, m, piperazine), 3.87 (3H, s,
OCH3) 2.12–2.56 (3H, m, CH3 piperazine), 6.90–8.28 {4H,
m, Aromatic proton (H5-quinolone and H4’, H5’, H7’-benzothi-
azole)}, 8.73 (1H, s, H2-quinolone), 9.03 (1H, s, NH), 15.06
(1H, s, COOH); IR (KBr): cm1 = 1585 (C = C), 1717
(C = O), 1254 (C–O), 1073 (C–N), 2917 (C–H), 3448
(COOH).
2.2.2.12. 1-Cyclopropyl-6-ﬂuoro-8-methoxy-7-(3-methyl-4-(N-
(6-nitro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-
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S572 P.C. Sharma et al.1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4l). M.p.
199–202 C (63% yield). 1H NMR (DMSO-d6): d/
ppm = 0.93 (4H, d, CH2–CH2–Cyclopropyl), 3.15 (1H, m,
CH Cyclopropyl), 3.28–3.85 (7H, m, piperazine), 2.18–2.65
(3H, m, CH3 piperazine), 3.96 (3H, s, OCH3), 7.16–8.00 {4H,
m, Aromatic proton (H5-quinolone and H4’, H5’, H7’-benzothi-
azole)}, 8.44 (1H, s, H2-quinolone), 9.76 (1H, s, NH), 15.35
(1H, s, COOH); IR (KBr): cm1 = 1586 (C = C), 1718
(C = O), 1249 (C–O), 1064 (C–N), 2947 (C–H), 3421
(COOH).
2.2.2.13. 1-Cyclopropyl-6-ﬂuoro-8-methoxy-7-(4-(N-(6-
methyl-1,3-benzothiazol-2-yl)amino-1-thio-methyl)-3-methylpi-
perazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
(4m). M.p. 197–200 C (63% yield). 1H NMR (DMSO-d6):
d/ppm = 1.22 (4H, d, CH2–CH2–Cyclopropyl), 2.92 (1H, m,
CH Cyclopropyl), 3.04–3.76 (7H, m, piperazine), 2.19–2.76
(3H, m, CH3 piperazine), 3.88 (3H, s, OCH3), 7.02–8.20 {4H,
m, Aromatic proton (H5-quinolone and H4’, H5’, H7’-benzothi-
azole)}, 8.78 (1H, s, H2-quinolone), 9.33 (1H, s, NH), 15.18
(1H, s, COOH); IR (KBr): cm1 = 1587 (C = C), 1715
(C = O), 1268 (C–O), 1109 (C–N), 2917 (C–H), 3413
(COOH); MS: m/z= 581.7 (M+).2.2.2.14. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-ben-
zothiazol-2-yl)amino-1-thio-methyl)-3-methylpiperazin-1-yl)-8-
methoxy-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4n).
M.p. 211–214 C (64% yield). 1H NMR (DMSO-d6): d/
ppm = 1.32 (4H, d, CH2–CH2–Cyclopropyl), 3.15 (1H, m,
CH Cyclopropyl), 3.37–3.81 (7H, m, piperazine), 2.80–2.98
(3H, m, CH3 piperazine), 3.94 (3H, s, OCH3), 6.98–7.94 {4H,
m, Aromatic proton (H5-quinolone and H4’, H5’, H7’-benzothi-
azole)}, 8.67 (1H, s, H2-quinolone), 9.28 (1H, s, NH), 15.17
(1H, s, COOH); IR (KBr): cm1 = 1583 (C = C), 1705
(C = O), 1265 (C–O), 1157 (C–N), 3194–2854 (C–H), 3302
(COOH); MS: m/z= 585.6 (M+).2.3. Biological evaluation
2.3.1. Antibacterial activity assay
The newly synthesized compounds (4a–4n) were evaluated
for antibacterial activities using agar well diffusion method
(McFarland, 1907) and by minimum inhibitory concentra-
tion (MIC) method (Kumar et al., 2009). Nutrient agar
media and King’s B media were used for the biological as-
say as per the following composition: Nutrient agar media
(NAM) made up of peptone 5 g, beef extract 3 g, NaCl
5 g, nutrient agar 2% and the ﬁnal volume of media was ad-
justed to 1000 ml with double distilled water (pH 7.0).
King’s B media containing peptone 2%, glycerol 1%,
KH2PO4 0.15%, MgSO4 0.15%, agar 2% and the ﬁnal vol-
ume of media was adjusted to 1000 ml with distilled water
(pH 7.0). Synthesized compounds were screened for antibac-
terial activities against two Gram-positive bacteria i.e. Staph-
ylococcus auerus (NCDC 110) and Bacillus subtilis (NCDC
71) and two Gram-negative bacteria i.e. E. coli (NCDC
134) and P. aeruginosa (NCDC 105). The bacterial cultures
were revived as per the protocol provided by the National
Collection of Dairy Cultures (NCDC) Karnal, India. P.
aeruginosa culture was maintained on King’s B media while
all other cultures were maintained on nutrient agar media.
Suspension of each test organism was prepared to evaluate
antibacterial activity of the synthetic compounds. All stock
cultures were stored at 4 C.
Each petri plate was prepared by pouring 40 ml of appro-
priate agar media. A ﬁxed volume (100 ll) of respective micro-
organism was spread on each petri plate with the help of a
spreader. In each seeded agar plate, wells were bored using a
borer of 6 mm diameter. Three concentrations (100, 50, and
10 lg/ml) of each compound reconstituted in dimethyl sulph-
oxide (DMSO) were added to the wells of seeded plates.
DMSO was used as a control for all the experiments. The
plates were kept in laminar air ﬂow for 15 min to allow
Table 2 Zone of inhibition in mm at 10, 50 and 100 lg/ml concentrations.
Compound S. auerus (NCDC 110) B. subtilis (NCDC 71) E. coli (NCDC 134) P. aeruginosa (NCDC 105)
10 50 100 10 50 100 10 50 100 10 50 100
4a – 2.5 5.0 – 8.0 8.5 – 5.8 6.5 2.5 3.3 5.3
4b – 5.0 6.0 – – – – – – 3.0 3.1 4.5
4c – – – – – 3.8 – – – 2.5 2.8 3.0
4d – 4.3 5.2 3.8 6.8 8.0 – 2.7 6.5 2.5 3.0 3.5
4e – 2.0 6.0 – – 4.3 – – – 3.0 3.3 3.4
4f – – 4.3 – 4.3 5.8 – – 4.5 3.0 3.5 3.7
4g 9.0 14.0 15.0 7.3 10.0 10.5 – 8.0 10.0 2.8 3.5 5.0
4h 4.3 7.5 10.0 6.5 10.0 11.0 10.3 14.8 15.0 2.8 6.8 7.1
4i 8.5 10.2 10.7 – 5.5 7.3 – 3.0 5.0 1.3 2.3 2.5
4j 11.3 12.8 15.0 7.5 9.0 10.3 7.8 11.0 13.3 3.3 3.8 5.0
4k – 4.2 5.7 – 2.8 3.0 – – 3.8 – - 3.8
4l – 5.5 7.5 – 2.8 5.0 – 4.0 3.5 3.8 3.8 5.0
4m – 2.7 5.0 – 3.8 4.5 – – – 1.5 3.3 4.0
4n 7.5 10.5 12.0 – 5.0 6.8 1.0 4.3 6.0 – 3.3 5.0
Norﬂoxacin 9.2 10.5 12.5 5.0 8.0 10.2 4.2 8.5 10.8 1.0 2.0 7.2
Ciproﬂoxacin 8.0 11.0 13.0 8.0 11.0 12.2 8.2 10.5 11.3 4.5 8.0 10.9
Gatiﬂoxacin 8.0 11.0 11.3 6.5 10.2 11.5 6.0 9.7 9.8 2.7 4.2 4.7
Control – – – – – – – – – – - -
Table 3 Minimum inhibitory concentration (MIC) in lg/ml against S. auerus, B. subtilis, E. coli, P. aeruginosa bacterial strains.
Compound S. auerus (NCDC 110) B. subtilis (NCDC 71) E. coli (NCDC 134) P. aeruginosa (NCDC 105)
4a 35 30 20 100
4b 05 120 140 120
4c 100 50 140 30
4d 40 15 05 30
4e 20 35 100 20
4f 30 10 30 110
4g 35 150 05 50
4h 10 30 175 20
4i 30 40 20 80
4j 15 25 35 35
4k 80 70 80 120
4l 05 15 20 35
4m 120 100 90 20
4n 25 55 05 20
Norﬂoxacin 10 05 70 15
Ciproﬂoxacin 50 20 25 60
Gatiﬂoxacin 05 100 100 50
Control – – – –
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incubated at 37 C for 16 h and antibacterial activity was
determined by measuring the diameter of inhibition zone. Each
test was performed in triplicates and mean diameter of zone of
inhibition was calculated. The results obtained were compared
against three standard drugs, i.e. ciproﬂoxacin, norﬂoxacin,
and gatiﬂoxacin.
MIC of the newly synthesized compounds was determined
using the method described by Kumar et al. (2009). A stock
solution of 3 mg/ml of each compound was prepared in
DMSO and further diluted to get a ﬁnal concentration ranging
from 200–0.05 lg/ml. Optical density was measured at 600 nm
using UV–visible spectrophotometer. The minimum concen-
tration, where no microbial growth was observed is called as
MIC of the compound.3. Results and discussion
The synthetic route of desired compounds is presented in
Scheme 1. The requisite 2-amino-6-substituted benzothiazoles
(2a–2e) were prepared according to the method described by
Stuckwisch (1949). Reaction between 2-amino-6-substituted
benzothiazole, different ﬂuoroquinolones and carbon disulﬁde
in the presence of basic medium composed of sodium bicar-
bonate and N,N-dimethyl formamide, afforded the target
compounds after a reﬂuxing time of 10 h. The ﬂuoroquinolone
derivatives (4a–4n) were found in 58–72% yields. TLC analysis
was done to conﬁrm the purity of the compound. Analytical
and spectral data (IR and 1H NMR) of all the newly synthe-
sized compounds were found in full agreement with the
proposed structures. In the 1H NMR spectra the signals of
S574 P.C. Sharma et al.the respective proton of the compounds were veriﬁed on the
basis of their chemical shifts, multiplicities. The spectra
showed a characteristic singlet of one proton in DMSO-d6 at
d 8.8–9.4 ppm corresponding to NH group of thiomide link-
age, proton at the second position of quinolone ring showed
a characteristic singlet at a shift at d 8.6–8.9 ppm and a broad
singlet at d 14.7–15.3 ppm of COOH group. The IR spectra of
compounds revealed C = O, C = C, stretching at approxi-
mately 1710, 1600 cm1, whereas in general C–O, O–H and
C–H bands were revealed at nearby 1300, 3400, 2900 and
3000. It was found interesting that only two compounds
among all were in lesser yield than 60% whereas all other
compounds are in good yields. Compound 1-ethyl-6-ﬂuoro-7-
(4-(N-(6-ﬂuoro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)
piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
was afforded in most effective yield of 72%. Melting range
of various compounds of this series is found to be higher than
200 C. Compound 4g showed the maximum melting temper-
ature among all synthesized compounds which is 332–335 C.
All the synthesized ﬂuoroquinolone derivatives were
screened for antibacterial activities against two Gram positive
bacterial strains i.e. S. auerus (NCDC 110) and Bacillus subtilis
(NCDC 71) and two Gram negative strains i.e. E. coli (NCDC
134) and P. aeruginosa (NCDC 105). The antibacterial activity
was determined by measuring the diameter of the zone of inhi-
bition and minimum inhibitory concentration (MIC). The
results of zone of inhibition and MIC screening are summa-
rized in Tables 2 and 3 respectively.
These novel derivatives demonstrated varying antibacterial
activity (zone of inhibition) against different strains. Com-
pound 4j possessing bromo functionality at position-6 of ben-
zothiazole nucleus, depicted signiﬁcant zone of inhibition of
11.3, 12.8 and 15.0 mm at 10, 50 and 100 lg/ml concentrations
respectively against S. auerus. Compounds bearing N-cyclo-
propyl functionality i.e. 4g, 4h, 4i and 4n also found to possess
signiﬁcantly potent antibacterial activities against S. auerus
and the zone of inhibition depicted by ciproﬂoxacin analogs
4g, 4i and 4j was even better than the standard antibiotics cip-
roﬂoxacin, norﬂoxacin, and gatiﬂoxacin when tested against S.
auerus. While compound 1-cyclopropyl-6-ﬂuoro-7-(4-(N-(6-
ﬂuoro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)-3-methylpi-
perazin-1-yl)-8-methoxy-1,4-dihydro-4-oxo-quinoline-3-car-
boxylic acid showed moderate activity. Compounds 4g,
substituted with the NO2 group at position-6 of benzothiazolyl
moiety annulated with ciproﬂoxacin molecule, depicted zone
of inhibition of 7.3 mm at concentration 10 lg/ml against
Gram positive Bacillus subtilis bacterial strain exhibit even bet-
ter activity than the standard drugs norﬂoxacin (5.0 mm) and
gatiﬂoxacin (6.5 mm). Compounds 4d, 4h and 4j exhibited
good antibacterial activities against Bacillus subtilis while 4g,
4h and 4j showed moderate activity and the activities shown
by 4h and 4j are signiﬁcantly potent having a zone of inhibition
of 10.3 and 7.8 mm respectively at concentration 10 lg/ml
against the standard antibiotics norﬂoxacin (4.2 mm) and gati-
ﬂoxacin (6.0 mm). Analogs 4h and 4j showed even better anti-
bacterial activities against the standard antibiotics
ciproﬂoxacin, norﬂoxacin and gatiﬂoxacin when tested against
E. coli and 1-cyclopropyl-6-ﬂuoro-7-(4-(N-(6-nitro-1,3-ben-
zothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-
dro-4-oxo-quinoline-3-carboxylic acid showed comparable
activities at higher concentration (50 lg/ml and 100 lg/ml).
Compounds 4b, 4e, 4f, 4g, 4h, 4j, 4l and 4m showed improvedantibacterial activities against the standard antibiotics norﬂox-
acin and gatiﬂoxacin when tested against P. aeruginosa.
When tested againstS. auerus compounds having nitro sub-
stitution at position-6 of benzothiazole clubbed with norﬂoxa-
cin (4b) and gatiﬂoxacin (4l) showed MIC 05 lg/ml, which is
10 times more potent as compared to the standard drug cipro-
ﬂoxacin (MIC value 50 lg/ml). While all the norﬂoxacin and
ciproﬂoxacin derivatives showed comparable activity. Com-
pounds 4a, 4c, 4e, 4h, 4i and 4j showed signiﬁcant MIC against
Bacillus subtilis when compared with standards. Moreover,
compounds 4d, 4f and 4l showed superior MIC (15, 10,
15 lg/ml respectively) against Bacillus subtilis than the stan-
dard antibiotics ciproﬂoxacin (MIC value 20 lg/ml) and gati-
ﬂoxacin (MIC value 100 lg/ml). Analogs 4g, 4i, 4l and 4n
showed better MIC against the standard antibiotics ciproﬂox-
acin, norﬂoxacin and gatiﬂoxacin when tested against E. coli.
Compounds 4c, 4d, 4e, 4g, 4h, 4j, 4l, 4m and 4n showed com-
parable MIC against the standard antibiotics norﬂoxacin and
gatiﬂoxacin when tested against P. aeruginosa.4. Conclusion
In conclusion, we have synthesized fourteen novel derivatives
of three ﬂuoroquinolone drugs i.e. norﬂoxacin, ciproﬂoxacin
and gatiﬂoxacin. These drugs have been linked to different
2-amino-6-substituted benzothiazoles via thiomide bridge
linkage. The derivatives are characterized by physicochemical
and spectral analyses such as 1H NMR and IR. The spectral
data obtained were in full agreement with the proposed struc-
tures. The in vitro evaluation of newly synthesized com-
pounds revealed improved therapeutic effectiveness as
compared to the parent drugs. Some derivatives showed more
potent or equipotent antibacterial activities against different
strains (S. auerus, B. subtilis, E. coli, P. aeruginosa). The
experimental data of this investigation reveal that the synthe-
sized novel derivatives of ﬂuoroquinolones have remarkable
antibacterial potential.References
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